申联生物
(688098)
| 流通市值：34.29亿 | | | 总市值：34.29亿 |
| 流通股本：4.11亿 | | | 总股本：4.11亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 64,884,767.68 | 72,772,211.43 | 121,995,777.63 | 74,266,451.73 |
| 交易性金融资产 | 705,984.4 | 10,520,418.77 | 32,823,934.27 | 60,398,472.24 |
| 应收票据及应收账款 | 316,141,075.45 | 296,158,932.43 | 282,108,584.13 | 325,449,214.38 |
| 其中：应收票据 | - | - | - | 137,570.4 |
| 应收账款 | 316,141,075.45 | 296,158,932.43 | 282,108,584.13 | 325,311,643.98 |
| 预付款项 | 1,360,632.33 | 1,694,460.31 | 1,096,491.74 | 2,347,238.47 |
| 其他应收款合计 | 2,795,269.87 | 3,309,538.58 | 3,326,636.05 | 4,056,745.21 |
| 存货 | 117,825,447.23 | 109,451,049.03 | 94,473,717.35 | 80,960,935.32 |
| 其他流动资产 | 4,219,591.94 | 1,244,633.6 | 76,685.88 | - |
| 流动资产合计 | 507,932,768.9 | 495,151,244.15 | 535,901,827.05 | 547,479,057.35 |
| 非流动资产: | | | | |
| 长期股权投资 | 87,094,711.61 | 66,456,157.58 | 21,459,327.95 | 22,616,464.96 |
| 其他权益工具投资 | 5,000,000 | 5,000,000 | 5,000,000 | 5,500,000 |
| 固定资产 | 735,816,318.9 | 755,400,194.95 | 702,859,870.3 | 718,420,144.13 |
| 在建工程 | 39,114,126.11 | 26,879,428.02 | 95,058,323.19 | 92,495,163.3 |
| 生产性生物资产 | 554,646.13 | 536,598.02 | 380,041.94 | 307,771.93 |
| 使用权资产 | 1,286,257.27 | 1,399,196.79 | 1,528,071.36 | 1,902,344.01 |
| 无形资产 | 122,532,291.18 | 122,119,867.97 | 124,695,272.51 | 124,684,173.38 |
| 开发支出 | 16,331,384.34 | 16,281,731.79 | 15,403,446.71 | 13,425,036.47 |
| 递延所得税资产 | 18,006,005.59 | 14,910,143.31 | 14,473,905.29 | 12,647,846.74 |
| 其他非流动资产 | 13,879,116.64 | 25,806,733.99 | 25,620,950.3 | 20,858,879.3 |
| 非流动资产合计 | 1,039,614,857.77 | 1,034,790,052.42 | 1,006,479,209.55 | 1,012,857,824.22 |
| 资产总计 | 1,547,547,626.67 | 1,529,941,296.57 | 1,542,381,036.6 | 1,560,336,881.57 |
| 流动负债: | | | | |
| 短期借款 | 52,364,228.23 | 12,887,674.33 | 12,887,674.33 | 13,447,280 |
| 应付票据及应付账款 | 13,053,735.46 | 20,343,699.48 | 16,425,715.84 | 11,377,085.97 |
| 应付账款 | 13,053,735.46 | 20,343,699.48 | 16,425,715.84 | 11,377,085.97 |
| 合同负债 | 9,269,480.62 | 7,346,397.01 | 17,818,035.16 | 12,151,630.12 |
| 应付职工薪酬 | 5,676,212.13 | 6,942,320.32 | 13,873,124.14 | 10,062,947.89 |
| 应交税费 | 521,630.55 | 5,136,977.13 | 1,483,156.08 | 3,694,644.92 |
| 其他应付款合计 | 52,032,305.25 | 61,765,077.89 | 61,840,646.37 | 66,231,486.79 |
| 应付股利 | 553,005.07 | 553,005.07 | 553,005.07 | 553,005.07 |
| 一年内到期的非流动负债 | 331,597.83 | 357,241.96 | 370,674.95 | 469,827.98 |
| 其他流动负债 | 10,196,004.36 | 9,066,060.24 | 8,629,187.33 | 10,690,867.97 |
| 流动负债合计 | 143,445,194.43 | 123,845,448.36 | 133,328,214.2 | 128,125,771.64 |
| 非流动负债: | | | | |
| 租赁负债 | 758,501.29 | 842,722.79 | 915,790.17 | 1,255,643.12 |
| 递延收益 | 8,121,482.4 | 8,614,726.89 | 9,107,971.38 | 9,601,215.87 |
| 递延所得税负债 | 33,569.18 | 29,884.81 | 58,078.88 | 434,549.57 |
| 非流动负债合计 | 8,913,552.87 | 9,487,334.49 | 10,081,840.43 | 11,291,408.56 |
| 负债合计 | 152,358,747.3 | 133,332,782.85 | 143,410,054.63 | 139,417,180.2 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 410,644,000 | 410,644,000 | 410,644,000 | 410,644,000 |
| 资本公积 | 535,804,857.83 | 539,233,471.91 | 539,233,471.91 | 539,233,471.91 |
| 减:库存股 | - | 20,004,297.06 | 20,004,297.06 | 20,004,297.06 |
| 盈余公积 | 75,020,487.07 | 75,020,487.07 | 75,020,487.07 | 75,020,487.07 |
| 未分配利润 | 365,080,255.03 | 382,495,704.28 | 384,226,659.18 | 404,999,713.72 |
| 归属于母公司股东权益合计 | 1,386,549,599.93 | 1,387,389,366.2 | 1,389,120,321.1 | 1,409,893,375.64 |
| 少数股东权益 | 8,639,279.44 | 9,219,147.52 | 9,850,660.87 | 11,026,325.73 |
| 股东权益合计 | 1,395,188,879.37 | 1,396,608,513.72 | 1,398,970,981.97 | 1,420,919,701.37 |
| 负债和股东权益合计 | 1,547,547,626.67 | 1,529,941,296.57 | 1,542,381,036.6 | 1,560,336,881.57 |
| 公告日期 | 2026-08-31 | 2026-04-29 | 2026-04-29 | 2025-10-27 |
| 审计意见(境内) | | | 标准无保留意见 | |